Neuro Spectrum Insights, Inc.

NeuroSpectrum Insights, Inc. filed Amendment No. 7 to its S-1 registration statement for an IPO of 3,750,000 shares of common stock at an expected price range of $4.00 to $5.00 per share, with an assumed midpoint of $4.50. The company plans to list on NYSE American under the symbol "NSIH." The offering is underwritten by Network 1 Financial Securities and Alexander Capital, with a 15% over-allotment option and underwriter warrants equal to 5% of shares sold at 125% of the IPO price.

Price data unavailable.

A pre-revenue company with no FDA diagnostic clearance and a conflicted underwriter is asking public investors to fund commercialization of an autism screening tool with unproven market demand.

This is a pre-revenue medical-device IPO in the autism diagnostics space, a niche with high unmet need but significant regulatory and reimbursement hurdles. Comparable early-stage neurodiagnostic companies have struggled with commercial adoption even after FDA clearance.

GyriCalc has FDA 510(k) marketing clearance but explicitly lacks FDA clearance for diagnostic use — a critical distinction for a product marketed as a diagnostic aid. The company has no revenue, accumulated deficit of $8.3M, and a going-concern risk given ongoing operating losses. The underwriter's